Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Obesity-drug maker Metsera Inc.’s stock jumped 47% on Friday as the biggest gainer among three initial public offerings bucking a swoon in the equity market to rise in their stock-market debuts ...

Jan. 27, 2025 — A study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future ... Signposting Children to ...

With obesity on the rise—a key risk factor for diseases like diabetes, hypertension, and cancer—Prime Minister Narendra Modi’s recent call to combat obesity and cut oil consumption has ...

Even still, expectations for the obesity market are immense, with analysts at Intron Health noting that Wegovy growth missed Wall Street expectations for the quarter by about 2%. For all of 2024 ...

Phase II topline results are expected in late 2024, with analysts anticipating data that could position MariTide competitively in the rapidly growing obesity treatment market. Some analysts ...

However, the survey highlights some key challenges, including stock market risks and AI disruptions ... ultra-processed foods in India is fuelling obesity, diabetes, and cardiovascular diseases.

Oil company Natural Resources and medical-device maker Beta Bionics also shrug off a down market to gain in their trading debuts Obesity-drug maker Metsera Inc.'s stock jumped 47% on Friday as the ...

Investors who had become concerned about an obesity market slowdown, as well as Novo’s competitive position, breathed a sigh of relief.